These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36140196)

  • 1. Multi-Functionalized Heteroduplex Antisense Oligonucleotides for Targeted Intracellular Delivery and Gene Silencing in HeLa Cells.
    Sousa de Almeida M; Rothen-Rutishauser B; Mayer M; Taskova M
    Biomedicines; 2022 Aug; 10(9):. PubMed ID: 36140196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA-RNA Heteroduplex Oligonucleotide for Highly Efficient Gene Silencing.
    Hara RI; Yoshioka K; Yokota T
    Methods Mol Biol; 2020; 2176():113-119. PubMed ID: 32865786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing.
    Nishina K; Piao W; Yoshida-Tanaka K; Sujino Y; Nishina T; Yamamoto T; Nitta K; Yoshioka K; Kuwahara H; Yasuhara H; Baba T; Ono F; Miyata K; Miyake K; Seth PP; Low A; Yoshida M; Bennett CF; Kataoka K; Mizusawa H; Obika S; Yokota T
    Nat Commun; 2015 Aug; 6():7969. PubMed ID: 26258894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly efficient silencing of microRNA by heteroduplex oligonucleotides.
    Yoshioka K; Kunieda T; Asami Y; Guo H; Miyata H; Yoshida-Tanaka K; Sujino Y; Piao W; Kuwahara H; Nishina K; Hara RI; Nagata T; Wada T; Obika S; Yokota T
    Nucleic Acids Res; 2019 Aug; 47(14):7321-7332. PubMed ID: 31214713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Separation-related rapid nuclear transport of DNA/RNA heteroduplex oligonucleotide: unveiling distinctive intracellular trafficking.
    Ono D; Asada K; Yui D; Sakaue F; Yoshioka K; Nagata T; Yokota T
    Mol Ther Nucleic Acids; 2021 Mar; 23():1360-1370. PubMed ID: 33738132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short DNA/RNA heteroduplex oligonucleotide interacting proteins are key regulators of target gene silencing.
    Asada K; Sakaue F; Nagata T; Zhang JC; Yoshida-Tanaka K; Abe A; Nawa M; Nishina K; Yokota T
    Nucleic Acids Res; 2021 May; 49(9):4864-4876. PubMed ID: 33928345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA.
    Huschka R; Barhoumi A; Liu Q; Roth JA; Ji L; Halas NJ
    ACS Nano; 2012 Sep; 6(9):7681-91. PubMed ID: 22862291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA/RNA heteroduplex oligonucleotide technology for regulating lymphocytes in vivo.
    Ohyagi M; Nagata T; Ihara K; Yoshida-Tanaka K; Nishi R; Miyata H; Abe A; Mabuchi Y; Akazawa C; Yokota T
    Nat Commun; 2021 Dec; 12(1):7344. PubMed ID: 34937876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functionalized bioengineered spider silk spheres improve nuclease resistance and activity of oligonucleotide therapeutics providing a strategy for cancer treatment.
    Kozlowska AK; Florczak A; Smialek M; Dondajewska E; Mackiewicz A; Kortylewski M; Dams-Kozlowska H
    Acta Biomater; 2017 Sep; 59():221-233. PubMed ID: 28694238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug delivery system of therapeutic oligonucleotides.
    Asami Y; Yoshioka K; Nishina K; Nagata T; Yokota T
    Drug Discov Ther; 2016; 10(5):256-262. PubMed ID: 27890899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Model Analysis and Simulation of Pharmacokinetics and
    Goto A; Yamamoto S; Igari T; Matsumoto SI; Chisaki I; Iida K; Nakayama M; Oda A; Kakoi Y; Uchida A; Miyata K; Nishikawa M; Nagata T; Kusuhara H; Yokota T; Hirabayashi H
    J Pharmacol Exp Ther; 2023 Jan; 384(1):197-204. PubMed ID: 36273821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential delivery of lipid-ligand conjugated DNA/RNA heteroduplex oligonucleotide to ischemic brain in hyperacute stage.
    Li F; Ichinose K; Ishibashi S; Yamamoto S; Iwasawa E; Suzuki M; Yoshida-Tanaka K; Yoshioka K; Nagata T; Hirabayashi H; Mogushi K; Yokota T
    Mol Ther; 2023 Apr; 31(4):1106-1122. PubMed ID: 36694463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA/RNA heteroduplex technology with cationic oligopeptide reduces class-related adverse effects of nucleic acid drugs.
    Ohara M; Nagata T; Hara RI; Yoshida-Tanaka K; Toide N; Takagi K; Sato K; Takenaka T; Nakakariya M; Miyata K; Maeda Y; Toh K; Wada T; Yokota T
    Mol Ther Nucleic Acids; 2024 Sep; 35(3):102289. PubMed ID: 39252874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic DNA/RNA heteroduplex oligonucleotide administration for regulating the gene expression of dorsal root ganglion and sciatic nerve.
    Kaburagi H; Nagata T; Enomoto M; Hirai T; Ohyagi M; Ihara K; Yoshida-Tanaka K; Ebihara S; Asada K; Yokoyama H; Okawa A; Yokota T
    Mol Ther Nucleic Acids; 2022 Jun; 28():910-919. PubMed ID: 35694210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of Gene Knockdown on CD22-Expressing Cells by Chemically Modified Glycan Ligand-siRNA Conjugates.
    Harumoto T; Iwai H; Tanigawa M; Kubo T; Atsumi T; Tsutsumi K; Takashima M; Destito G; Soloff R; Tomizuka K; Nycholat C; Paulson J; Uehara K
    ACS Chem Biol; 2022 Feb; 17(2):292-298. PubMed ID: 35020348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronan-based delivery of therapeutic oligonucleotides for treatment of human diseases.
    Ossipov DA
    Expert Opin Drug Deliv; 2019 Jun; 16(6):621-637. PubMed ID: 31072142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-Engineering RNA Molecules into Therapeutic Agents.
    Egli M; Manoharan M
    Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
    Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
    J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of blood-brain barrier function by a heteroduplex oligonucleotide in vivo.
    Kuwahara H; Song J; Shimoura T; Yoshida-Tanaka K; Mizuno T; Mochizuki T; Zeniya S; Li F; Nishina K; Nagata T; Ito S; Kusuhara H; Yokota T
    Sci Rep; 2018 Mar; 8(1):4377. PubMed ID: 29531265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.